| Withdrawn | Study of the Safety of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alzheimer's Disease C Alzheimer's Disease, Dementia, Cognition | Phase 2 | 2015-07-01 |
| Unknown | Study to Assess the Safety, Tolerability, and Pharmacodynamic (PD) Effects of FRM-0334 in Subjects With Prodro Granulin Mutation | Phase 2 | 2014-10-01 |
| Completed | Study to Assess the Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) Effects of EVP-6308 an Schizophrenia | Phase 1 | 2014-06-01 |
| Terminated | Study of the Safety and Clinical Effects of 2 Doses of EVP-6124 in Subjects With Alzheimer's Disease Who Compl Alzheimer's Disease, Dementia | Phase 3 | 2014-06-01 |
| Terminated | Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alz Alzheimer's Disease, Dementia | Phase 3 | 2013-10-01 |
| Completed | Study of EVP-6308 to Assess the Dose- and Concentration-dependent Displacement of [18F]MNI-659 by EVP-6308 Healthy | Phase 1 | 2013-10-01 |
| Terminated | Study of the Safety and Effectiveness of Two Doses of Investigational Study Drug EVP-6124 in Subjects With Alz Alzheimer's Disease, Dementia | Phase 3 | 2013-10-01 |
| Completed | EVP-6124 Renal Impairment Study Renal Impairment | Phase 1 | 2013-06-01 |
| Completed | EVP-6124 Hepatic Impairment Study Hepatic Impairment | Phase 1 | 2013-06-01 |
| Completed | A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophreni Schizophrenia, Impaired Cognition | Phase 3 | 2013-06-01 |
| Completed | Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Co Mild Cognitive Impairment, Alzheimer's Disease | Phase 2 | 2012-11-01 |
| Completed | Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chroni Schizophrenia, Impaired Cognition | Phase 3 | 2012-10-01 |
| Completed | Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chroni Schizophrenia, Impaired Cognition | Phase 3 | 2012-10-01 |
| Completed | Phase 1 Study to Assess the Effects of EVP-6124 on the QT/QTc Interval in Healthy Subjects Healthy Subjects, Cardiac Repolarization | Phase 1 | 2011-12-01 |
| Completed | Safety and Cognitive Function Study of EVP-6124 in Patients With Mild to Moderate Alzheimer's Disease Alzheimer's Disease, Central Nervous System Diseases, Cognition | Phase 2 | 2010-04-01 |
| Completed | Safety and Cognitive Function Study of EVP-6124 in Patients With Schizophrenia Schizophrenia, Central Nervous System Diseases, Cognition | Phase 2 | 2009-12-01 |
| Completed | Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease Alzheimer's Disease, Central Nervous System Diseases | Phase 1 | 2008-10-01 |
| Completed | Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Schizophrenia Schizophrenia, Schizoaffective Disorder, Central Nervous System Diseases | Phase 1 | 2008-04-01 |